ProCE Banner Activity

STOP-VEN: Discontinuation of Venetoclax + Azacitidine for Patients With AML in Remission at Time of Treatment Interruption

Conference Coverage

In a retrospective analysis, discontinuation of venetoclax plus azacitidine during AML remission was associated with a sustained treatment-free remission and OS in patients with newly diagnosed or relapsed/refractory AML.

Released: December 11, 2023


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AbbVie Inc., AstraZeneca, Daiichi Sankyo, Inc., Merck Sharp & Dohme LLC, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc, and Seagen Inc.

AbbVie Inc.


Daiichi Sankyo, Inc.

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation

Regeneron Pharmaceuticals, Inc

Seagen Inc.